Overview
Wegovy® is a prescription medication containing semaglutide, a GLP-1 receptor agonist. It is approved for chronic weight management in adults and adolescents aged 12 years and older with obesity or overweight conditions, especially when accompanied by weight-related comorbidities. Additionally, Wegovy® is indicated to reduce the risk of major adverse cardiovascular events (MACE) such as heart attack, stroke, or cardiovascular death in adults with established cardiovascular disease and either obesity or overweight.





